CDR-Life Announces First Milestone Achievement in Boehringer Ingelheim Autoimmune Partnership

Milestone advances antibody-based program for autoimmune diseases

ZURICH--(BUSINESS WIRE)--CDR-Life, Inc., a clinical-stage biotechnology company developing highly selective T cell engagers (TCEs) to treat cancer and autoimmune diseases, today announced achievement of the first preclinical milestone under its 2025 license agreement with Boehringer Ingelheim. This milestone marks continued progress in the companies’ efforts to develop next-generation antibody-based therapies for autoimmune diseases.

The candidate is a trispecific M-gager®, an antibody-based T cell engager designed to selectively target and deplete B cells with the goal of achieving an immune system reset. Dysregulated B cells are key drivers in many autoimmune and inflammatory diseases, including lupus, multiple sclerosis and certain forms of arthritis, making deep and selective B-cell depletion a promising therapeutic strategy across multiple indications.

The milestone was achieved following in vitro and in vivo preclinical proof of concept studies. Based on these results, Boehringer Ingelheim has elected to proceed with further development of the candidate.

“This milestone reflects the strength of our antibody-derived platform and its ability to rapidly generate highly potent, selective molecules,” said Christian Leisner, PhD, Chief Executive Officer of CDR-Life. “We are excited to see continued momentum in our partnership with Boehringer Ingelheim and look forward to further advancements of this program.”

The partnership combines CDR-Life’s proprietary antibody fragment technology and M-gager platform with Boehringer Ingelheim’s global expertise in drug development to advance novel therapeutic approaches aimed at selectively targeting disease-driving immune cells. The Licensing deal was first announced in November 2025.

About CDR-Life
CDR-Life develops highly targeted T cell engagers (TCEs) for the treatment of solid cancers and autoimmune diseases. Our M-gager® platform delivers TCEs against challenging but clean targets through unparalleled binding-specificity. With our first oncology program now in clinical trials, we are advancing a pipeline of potent and selective TCE therapeutics. Our longstanding collaboration with Boehringer Ingelheim on a molecule derived from our M-gager® platform, now in Phase 2, demonstrates the potential of our antibody-derived molecules. The partnership between the companies expanded further in 2025 through a new global licensing agreement to develop a trispecific M-gager for autoimmune diseases. Backed by leading cross-Atlantic investors, our team is committed to bringing life-changing, disease-modifying medicines to patients globally. Learn more at www.CDR-Life.com